Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, David L. Rimm, Kurt A. Schalper et al.|Laboratory Investigation|2013Cited by 753
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Thanh Tran et al.|The Lancet Respiratory Medicine|2022Cited by 127
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, Dimitrios Bafaloukos, Sofia Lampaki et al.|Cancer Immunology Immunotherapy|2021Cited by 39
Figure S1 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis Vathiotis, David L. Rimm, Myrto Moutafi et al.|Unknown|2023Cited by 0
Figure S4 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis Vathiotis, David L. Rimm, Myrto Moutafi et al.|Unknown|2023Cited by 0